Kampman K M, Volpicelli J R, Mulvaney F, Alterman A I, Cornish J, Gariti P, Cnaan A, Poole S, Muller E, Acosta T, Luce D, O'Brien C
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Drug Alcohol Depend. 2001 Jun 1;63(1):69-78. doi: 10.1016/s0376-8716(00)00193-9.
Propranolol may reduce symptoms of autonomic arousal associated with early cocaine abstinence and improve treatment outcome. This trial was an 8-week, double-blind, placebo-controlled trial of propranolol in 108 cocaine dependent subjects. The primary outcome measure was quantitative urinary benzoylecgonine levels. Secondary outcome measures included treatment retention, addiction severity index results, cocaine craving, mood and anxiety symptoms, cocaine withdrawal symptoms, and adverse events. Propranolol treated subjects had lower cocaine withdrawal symptom severity but otherwise did not differ from placebo treated subjects in any outcome measure. However, in a secondary, exploratory analysis, subjects with more severe cocaine withdrawal symptoms responded better to propranolol in comparison to placebo. In these subjects, propranolol treatment was associated with better treatment retention and lower urinary benzoylecgonine levels as compared with the placebo treatment. Propranolol may be useful only for the treatment of cocaine dependent patients with severe cocaine withdrawal symptoms.
普萘洛尔可能会减轻与早期可卡因戒断相关的自主神经兴奋症状，并改善治疗效果。本试验是一项为期8周的双盲、安慰剂对照试验，对108名可卡因依赖者使用了普萘洛尔。主要结局指标是尿中苯甲酰芽子碱的定量水平。次要结局指标包括治疗保留率、成瘾严重程度指数结果、对可卡因的渴望、情绪和焦虑症状、可卡因戒断症状以及不良事件。接受普萘洛尔治疗的受试者可卡因戒断症状严重程度较低，但在任何结局指标上与接受安慰剂治疗的受试者并无差异。然而，在一项次要的探索性分析中，与安慰剂相比，可卡因戒断症状更严重的受试者对普萘洛尔的反应更好。在这些受试者中，与安慰剂治疗相比，普萘洛尔治疗与更好的治疗保留率和更低的尿中苯甲酰芽子碱水平相关。普萘洛尔可能仅对有严重可卡因戒断症状的可卡因依赖患者的治疗有用。
